Clinical Trial

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

Study acronym: COMBo
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-03; most recent amendment 2026-04-06.
Trial Details
NCT Number NCT07280702
Lead Sponsor University of Texas Southwestern Medical Center
Conditions Psoriatic Arthritis (PsA)
Enrollment 128 participants
Start Date 2026-04-15
Primary Completion 2027-12-15 (estimated)
Study Completion 2027-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-13